Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hohlfeld

Showing results (11-20 of 206) with videos related to

Pageof 21
Sort By:
Neurology|February 20, 1999
Myasthenia gravis: cell transfer from man to mouseR Hohlfeld
International MS Journal|February 24, 2004
The prospects for neuroprotection in MSR Hohlfeld
Der Nervenarzt|January 23, 2009
[B lymphocytes: a new "target" in treatment for multiple sclerosis]R Hohlfeld
Der Nervenarzt|February 1, 1991
[Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]R Hohlfeld
Der Nervenarzt|June 4, 1999
[Immunotherapy of multiple sclerosis. Consensus and controversies]R Hohlfeld
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|December 22, 1999
Therapeutic strategies in multiple sclerosis. I. ImmunotherapyR Hohlfeld
Medizinische Klinik (Munich, Germany : 1983)|October 18, 2001
[Betaferon and therapy of multiple sclerosis--present and future]R Hohlfeld
Brain : a Journal of Neurology|May 1, 1997
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectivesR Hohlfeld
Annals of Neurology|June 1, 1989
Neurological autoimmune disease and the trimolecular complex of T-lymphocytesR Hohlfeld
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2021
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - CommentaryR Hohlfeld
Pageof 21

Showing results (11-20 of 206) with videos related to

Sort By:
Pageof 21
Neurology|February 20, 1999
Myasthenia gravis: cell transfer from man to mouseR Hohlfeld
International MS Journal|February 24, 2004
The prospects for neuroprotection in MSR Hohlfeld
Der Nervenarzt|January 23, 2009
[B lymphocytes: a new "target" in treatment for multiple sclerosis]R Hohlfeld
Der Nervenarzt|February 1, 1991
[Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]R Hohlfeld
Der Nervenarzt|June 4, 1999
[Immunotherapy of multiple sclerosis. Consensus and controversies]R Hohlfeld
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|December 22, 1999
Therapeutic strategies in multiple sclerosis. I. ImmunotherapyR Hohlfeld
Medizinische Klinik (Munich, Germany : 1983)|October 18, 2001
[Betaferon and therapy of multiple sclerosis--present and future]R Hohlfeld
Brain : a Journal of Neurology|May 1, 1997
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectivesR Hohlfeld
Annals of Neurology|June 1, 1989
Neurological autoimmune disease and the trimolecular complex of T-lymphocytesR Hohlfeld
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2021
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - CommentaryR Hohlfeld
Pageof 21